These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Walenga JM Clin Adv Hematol Oncol; 2007 Oct; 5(10):759-60. PubMed ID: 17998892 [No Abstract] [Full Text] [Related]
9. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke. Padma V; Fisher M; Moonis M Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101 [TBL] [Abstract][Full Text] [Related]
13. [New medical anticoagulants]. Choussat R; Montalescot G Rev Mal Respir; 1999 Nov; 16(5 Pt 2):985-95. PubMed ID: 10907447 [TBL] [Abstract][Full Text] [Related]
14. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding. Buchanan MR; Brister SJ Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889 [TBL] [Abstract][Full Text] [Related]
15. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Meddahi S; Bara L; Fessi H; Samama MM Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099 [TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparins: do we have the GUSTO to identify differences between alternative formulations? Zakarija A; Bennett CL Arch Intern Med; 2005 Apr; 165(7):722-3. PubMed ID: 15824289 [No Abstract] [Full Text] [Related]
17. The effect of taurolidine on experimental thrombus formation. Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549 [TBL] [Abstract][Full Text] [Related]
18. [Heparin therapy: 1998 (current use of the 80-year-old heparin)]. Rák K Orv Hetil; 1999 Jan; 140(2):59-66. PubMed ID: 9949661 [TBL] [Abstract][Full Text] [Related]